Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08049820 in Healthy Adult Participants
NCT06686797Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-08049820 in atopic dermatitis (AD) (9 cohorts), sponsored by Pfizer. Primary endpoints: Treatment Emergent Adverse Events at Day 45, Serious Adverse Events at Day 45 and 3 more. Started Nov 2024; status: completed.
02
Drugs
PF-08049820
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06686797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06686797.